Get the Stockscreener App
9.77
4.87%
-0.50
After Hours:
9.85
0.08
+0.82%
Kura Oncology Inc stock is traded at $9.77, with a volume of 4.23M.
It is down -4.87% in the last 24 hours and up +2.09% over the past month.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.
See More
Previous Close:
$10.27
Open:
$10.22
24h Volume:
4.23M
Relative Volume:
2.24
Market Cap:
$848.01M
Revenue:
-
Net Income/Loss:
$-168.09M
P/E Ratio:
-4.5023
EPS:
-2.17
Net Cash Flow:
$-138.01M
1W Performance:
-11.50%
1M Performance:
+2.09%
6M Performance:
+51.00%
1Y Performance:
-42.12%
1-Day Range:
$8.94
$10.36
1-Week Range:
$8.94
$11.05
52-Week Range:
$5.41
$19.73
Kura Oncology Inc Stock (KURA) Company Profile
Name
Kura Oncology Inc
Sector
Industry
Phone
(858) 500-8800
Address
12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO, CA
Compare KURA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
9.77 | 891.41M | 0 | -168.09M | -138.01M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-04-25 | Initiated | Guggenheim | Neutral |
| Feb-06-25 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-14-24 | Downgrade | Stifel | Buy → Hold |
| Dec-22-23 | Initiated | Mizuho | Buy |
| Aug-11-23 | Initiated | BofA Securities | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Perform |
| May-17-23 | Initiated | BTIG Research | Buy |
| Jan-31-23 | Initiated | Stifel | Buy |
| Jul-12-22 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-15-22 | Initiated | Jefferies | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-07-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-03-20 | Initiated | Stifel | Buy |
| Nov-05-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Initiated | Credit Suisse | Outperform |
| May-05-20 | Initiated | Barclays | Overweight |
| Jul-18-19 | Initiated | Deutsche Bank | Buy |
| Nov-09-18 | Initiated | Piper Jaffray | Overweight |
| Aug-01-18 | Initiated | H.C. Wainwright | Buy |
| Oct-13-16 | Resumed | Leerink Partners | Outperform |
| Jan-22-16 | Initiated | JMP Securities | Mkt Outperform |
| Dec-30-15 | Initiated | Oppenheimer | Outperform |
| Dec-16-15 | Initiated | Citigroup | Buy |
View All
Kura Oncology Inc Stock (KURA) Latest News
Kura Oncology (Nasdaq: KURA) receives $30M as second KOMET-017 Phase 3 doses first patient - Stock Titan
Candlestick signals on Kura Oncology Inc. stock todayPortfolio Update Report & Breakout Confirmation Trade Signals - newser.com
Kura Oncology to present ziftomenib combination data at ASH meeting - Investing.com
Kura Oncology (NASDAQ: KURA) to present oral ziftomenib ven/aza data in AML at ASH - Stock Titan
Why Kura Oncology Inc. stock attracts high net worth investorsWeekly Profit Report & Free Real-Time Volume Trigger Notifications - newser.com
What To Expect From Kura Oncology Inc (KURA) Q3 2025 Earnings - GuruFocus
Signal strength of Kura Oncology Inc. stock in tech scannersJuly 2025 Volume & Risk Managed Investment Signals - newser.com
Is Kura Oncology (NASDAQ:KURA) Weighed On By Its Debt Load? - simplywall.st
How Kura Oncology Inc. stock reacts to Fed rate cutsPortfolio Profit Report & Expert Verified Movement Alerts - newser.com
How to monitor Kura Oncology Inc. with trend dashboards2025 Market Outlook & Daily Profit Maximizing Trade Tips - newser.com
What momentum indicators show for Kura Oncology Inc. stockMarket Growth Summary & Free Weekly Chart Analysis and Trade Guides - newser.com
Can technical indicators confirm Kura Oncology Inc.’s reversalMarket Activity Summary & Weekly High Return Stock Forecasts - newser.com
Applying sector rotation models to Kura Oncology Inc.July 2025 Movers & Safe Capital Growth Tips - newser.com
Understanding Kura Oncology Inc.’s price movement2025 Market WrapUp & Daily Profit Maximizing Trade Tips - newser.com
Kura Oncology's Ziftomenib Poised For Differentiation (NASDAQ:KURA) - Seeking Alpha
What drives Kura Oncology Inc stock priceGap Up/Gap Down Analysis & Tap Into the Fastest-Growing Companies - earlytimes.in
Is Kura Oncology Inc. showing signs of accumulationJuly 2025 Decliners & High Conviction Buy Zone Picks - newser.com
What analysts say about Kura Oncology Inc stockGap Up/Gap Down Analysis & Follow Top Performers in the Community - earlytimes.in
Can Kura Oncology Inc. stock resist market sell offs2025 Retail Activity & Weekly High Return Stock Opportunities - newser.com
Kura Oncology (KURA) to Release Earnings on Thursday - MarketBeat
Kura Oncology Inc. stock momentum explained2025 Price Targets & Low Risk Entry Point Tips - newser.com
Can Kura Oncology Inc. stock rebound after recent weaknessJuly 2025 Short Interest & Capital Efficiency Focused Strategies - newser.com
Kura Oncology’s KO-2806 Study: A New Hope for Advanced Solid Tumors? - The Globe and Mail
Kura Oncology (NASDAQ:KURA) Shares Up 9.1%Still a Buy? - MarketBeat
Kura Oncology to Report Third Quarter 2025 Financial Results - The Manila Times
Kura Oncology Inc Stock (KURA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):